OncoSec Medical (NASDAQ:ONCS) had its price objective cut by equities researchers at Piper Jaffray Companies from $5.00 to $3.00 in a report released on Tuesday, The Fly reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Piper Jaffray Companies’ target price indicates a potential upside of 248.84% from the company’s current price.
Several other equities analysts also recently commented on ONCS. HC Wainwright set a $4.00 target price on OncoSec Medical and gave the company a “buy” rating in a research report on Monday, October 22nd. Dawson James reiterated a “buy” rating on shares of OncoSec Medical in a research report on Monday, July 16th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $4.00.
OncoSec Medical stock opened at $0.86 on Tuesday. The stock has a market capitalization of $51.72 million, a price-to-earnings ratio of -0.81 and a beta of 2.28. OncoSec Medical has a 12 month low of $0.68 and a 12 month high of $2.95.
OncoSec Medical Company Profile
OncoSec Medical Incorporated, a biotechnology company, engages in developing DNA-based intratumoral immunotherapies in the United States. The company's investigational technology, ImmunoPulseis designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or tavo) for the treatment of cancer.
Further Reading: How does inflation affect different investments?
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.